Procaine HCl

Catalog No.S4023 Synonyms: Novocaine HCl

For research use only.

Procaine (Novocaine) is an inhibitor of sodium channel, NMDA receptor and nAChR with IC50 of 60 μM, 0.296 mM and 45.5 μM, which is also an inhibitor of 5-HT3 with KD of 1.7 μM.

Procaine HCl Chemical Structure

CAS No. 51-05-8

Selleck's Procaine HCl has been cited by 1 Publication

1 Customer Review

Purity & Quality Control

Choose Selective Sodium Channel Inhibitors

Other Sodium Channel Products

Biological Activity

Description Procaine (Novocaine) is an inhibitor of sodium channel, NMDA receptor and nAChR with IC50 of 60 μM, 0.296 mM and 45.5 μM, which is also an inhibitor of 5-HT3 with KD of 1.7 μM.
Targets
5-HT3 [4] nAChR [3] Sodium channel [1] NMDA receptor [2]
1.7 μM(Kd) 45.5 μM 60 μM 0.296 mM
In vitro

Procaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. [1] Procaine has also been shown to bind or antagonize the function of N-methyl-D-aspartate (NMDA) receptors [2] as well as nicotinic acetylcholine receptors [3] and the serotonin receptor-ion channel complex. [4] Procaine is an inhibitor of the mechanisms of Ca-induced Ca release and caffeine-induced Ca release in various types of muscle preparations. 0.5 mM Procaine blocks individual sarcoplasmic reticulum Ca2+ release channels in planarlipid bilayers. Procaine does not reduce the single channel conductance nor appreciably shorts the mean open times of the channel, rather, it increases the longest closed time. [5] Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. 0.5 mM Procaine produces a 40% reduction in 5-methylcytosine DNA in MCF-7 breast cancer cell line. Procaine can also bind to CpG-enriched DNA, and demethylates densely hypermethylated CpG islands, leading to restoring gene expression of epigenetically silenced genes. Procaine treatment (0.5 mM) induces an increase in the mitotic index of cells in M phase. Procaine treatment (1 mM) reduces cell proliferation by ~40%. [6] Procaine influences red cell shape and deformability. 45 mM Procaine almost completely prevents the discocyte-echinocyte transformation associated with ATP depletion. Similar concentrations of Procaine normalize the viscosity and filterability, but have no effect on cell volume, osmotic fragility, or monovalent cation composition of cells undergoing ATP depletion. [7]

In vivo Procaine is an excitant of limbic system cells. 15 mg/kg Procaine increases cellular activity in amygdala ventral hippocampus, nucleus accumbens, temporal neocortex and ventromedial hypothalamus of awaken cat. Procaine facilitates transmission of evoked excitatory activity from the amygdala to the ventromedial hypothalamus. [8] Procaine influences frequency and amplitude of reticularly elicited hippocampal rhythmical slow activity. Procaine (0.5 μL, 20% wt/vol) injected at points in the ascending system anterior to the supramamillary nucleus, in the region of the medial forebrain bundle or in the medial septum, reduces the amplitude of reticularly elicited rhythmical slow activity (RSA) but has no effect on its frequency. Procaine injected at points in the ascending system from just anterior to the reticular formation stimulation site, up to, and including the supramamillary nucleus, reduces both the frequency and amplitude of reticularly elicited RSA. [9] Procaine (80mg/kg) increases the duration and propagation of epileptiform afterdischarges (ADs) produced by electrical stimulation of the amygdala in rats. Porcaine also increases the rate of seizure development (kindling) produced by repeated stimulation of the amygdala. Procaine would itself act as convulsants in well kindled subjects. Procaine produces a weak but significant increase in the amplitude of the transcallosal evoked potential. [10] Procaine influences generation of auditory brain stem responses (ABRs). Procaine (30 μL of 1% solution) injection into the trapezoid body of guinea pig affects many of the components of the scalp-derived ABR: N2 is delayed making P2 broader in duration, P3 and N3 are lost, P4 is shortened in latency, broadened in duration but unaffected in amplitude, and N4 is considerably attenuated. Only P1 and N1 are unaffected by the procaine injection. [11] Procaine increases the therapeutic index of cisplatin by improving antitumor activity of cisplatin and reducing its nephrotoxicity. Simultaneous administration of cisplatin and Procaine (40 mg/kg) to BDF1 mice produces 50% lethal dose (LD50) and 90% lethal dose (LD90) values approximately two times higher than those observed with cisplatin alone. Simultaneous administration produces a higher cure rates compared with cisplatin alone (50% vs 9%). The increased blood urea nitrogen (BUN) levels observed 4-7 days following a single administration of cisplatin, as well as the tubular degenerative changes detected by light microscopy, are not observed when the same doses of cisplatin are given simultaneously with Procaine. [12]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 272.77
Formula

C13H20N2O2.HCl

CAS No. 51-05-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03805503 Completed Drug: Chloroprocaine 1% Injectable Solution Spinal Anesthesia University Hospital Ghent September 16 2015 Phase 4
NCT02287870 Completed Drug: Chloroprocaine|Drug: Lidocaine Anesthesia Jinling Hospital China January 2008 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-11-29)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Procaine HCl | Procaine HCl supplier | purchase Procaine HCl | Procaine HCl cost | Procaine HCl manufacturer | order Procaine HCl | Procaine HCl distributor